Treatment of type 2 diabetes with the designer cytokine IC7Fc
Maria Findeisen, Tamara L Allen, Darren C Henstridge, Helene Kammoun, Amanda E Brandon, Laurie L Baggio, Kevin I Watt, Martin Pal, Lena Cron, Emma Estevez, Christine Yang, Greg M Kowalski, Liam O'Reilly, Casey Egan, Emily Sun, May Thai Le, Guy Krippner, Timothy E Adams, Robert S Lee, Joachim Groetzinger Show all
Nature | NATURE PUBLISHING GROUP | Published : 2019
Awarded by National Health & Medical Research Council of Australia
Awarded by CIHR
Awarded by DFG
Awarded by Deutsche Forschungsgemeinschaft (DFG), Bonn
This study was funded, in part, by the National Health & Medical Research Council of Australia (project grant 526606 and APP1156511 to M.A.F. and S.R.-J.; project grant APP1039502 to M.A.F.; development grant APP1039502 to M.A.F., T.E.A. and M.A.C.; principal research fellowship 445302 to M.A.F., senior principal research fellowship (SPRF) APP1021168 to M.A.F. and SPRF APP1116936 to M.A.F. This project was also funded, in part, by a CASS Foundation grant awarded to T.L.A. and M.A.F. and CIHR foundation grant 164321 to D.J.D. The project was also supported in part by the Victorian Government's OIS Program. We thank F.T. Wunderlich and C.M. Wunderlich for providing reagents to generate the ROSA26-IC7Fc mouse, as well as A. Nenci and J. Gonzales from the Monash Gene Targeting Facility. M.P. was supported by a research fellowship (DFG, PA-2459/1-1). We thank J. Scoble and L. Sparrow for their help in preparing PEGylated forms of IC7, J. Bentley for help with europium assays, X. Xiao and G. Lovrecz for mammalian cell line development and scale-up, L. Pontes-Braz for protein purification and the Burnet ImmunoMonitoring Facility for conducting the human PBMC experiments. The work of S.R.-J. was funded by the Deutsche Forschungsgemeinschaft (DFG), Bonn (grant no.: SFB841, project C1; grant no.: SFB877, project A1), and by the Cluster of Excellence 'Inflammation at Interfaces'.